LEADER 00865nam0-2200325---450 001 990009468860403321 005 20200918110615.0 010 $a978-81-7622-228-0 035 $a000946886 035 $aFED01000946886 035 $a(Aleph)000946886FED01 035 $a000946886 100 $a20111027d2011----km-y0itay50------ba 101 0 $aeng 102 $aIN 105 $aa-------001yy 200 1 $aCrop physiology$fG. C. Srivastava 210 $aDelhi$cBiotech Books$d2011 215 $aVII, 205 p.$cill.$d24 cm 610 0 $aFisiologia vegetale 676 $a581.1$v20$zita 676 $a571.2$v23$zita 700 1$aSrivastava$bG. C.$0513941 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009468860403321 952 $a60 571.2 SRIG 2011$b13518$fFAGBC 959 $aFAGBC 996 $aCrop physiology$9852797 997 $aUNINA LEADER 04630nam 2200697 a 450 001 9910953430403321 005 20251017110221.0 010 $a0-309-21493-9 010 $a1-283-25354-2 010 $a9786613253545 010 $a0-309-21491-2 035 $a(CKB)2550000000051836 035 $a(EBL)3378855 035 $a(SSID)ssj0000533788 035 $a(PQKBManifestationID)11319018 035 $a(PQKBTitleCode)TC0000533788 035 $a(PQKBWorkID)10504138 035 $a(PQKB)10851009 035 $a(MiAaPQ)EBC3378855 035 $a(Au-PeEL)EBL3378855 035 $a(CaPaEBR)ebr10495455 035 $a(CaONFJC)MIL325354 035 $a(OCoLC)923284117 035 $a(DNLM)1571930 035 $a(EXLCZ)992550000000051836 100 $a20111003d2011 uy 0 101 0 $aeng 135 $auruz#---auuu| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvancing regulatory science for medical countermeasure development $eworkshop summary /$fTheresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$d2011 215 $a1 online resource (150 pages) 300 $aDescription based upon print version of record. 311 08$a0-309-21490-4 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""1 Introduction""; ""2 MCM Enterprise and Stakeholder Perspectives""; ""3 Cutting-Edge Efforts to Advance MCM Regulatory Science""; ""4 MCM Regulatory Science Needs for At-Risk Populations""; ""5 Crosscutting Themes and Future Directions""; ""6 Closing Remarks""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies"" 330 $aWhether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing regulatory science for medical countermeasure development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing regulatory science for medical countermeasure development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description. 606 $aEmergency management$zUnited States$xEvaluation$vCongresses 606 $aDisaster medicine$zUnited States$xEvaluation$vCongresses 606 $aWeapons of mass destruction$xHealth aspects$vCongresses 606 $aChemical agents (Munitions)$vCongresses 615 0$aEmergency management$xEvaluation 615 0$aDisaster medicine$xEvaluation 615 0$aWeapons of mass destruction$xHealth aspects 615 0$aChemical agents (Munitions) 676 $a616.0250973 701 $aWizemann$b Theresa M$0890630 701 $aAltevogt$b Bruce M$01791694 701 $aClaiborne$b Anne B$01805914 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.).$bForum on Medical and Public Health Preparedness for Catastrophic Events. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910953430403321 996 $aAdvancing regulatory science for medical countermeasure development$94446304 997 $aUNINA